PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

Shares of PTC Inc. (NASDAQ:PTC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Four ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...

Covestor Ltd lifted its stake in shares of PTC Inc. (NASDAQ:PTC – Free Report) by 70.8% in the 3rd quarter, according to the ...

StockNews.com downgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a buy rating to a hold rating in a ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the ...

Seaport-based PTC Inc. (Nasdaq: PTC), one of the state's largest public companies by revenue, added 270 workers in the 12 ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the design software stocks, including PTC (NASDAQ:PTC) ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ...